{
    "nctId": "NCT04188548",
    "briefTitle": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer",
    "officialTitle": "EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\nAll study parts:\n\n* Participants must be willing to provide adequate archival tissue sample\n* Participants must be willing to use highly effective birth control\n* Participants must have adequate organ function\n* Participants must be able to swallow capsules\n\nDose escalation- Participants must have one of the following:\n\n* Parts A and B: ER+ HER2- breast cancer with evidence of locally advanced unresectable or metastatic disease who have had the following:\n* Part A: may have had up to 1 prior regimen of any kind for in the advanced/metastatic setting and no prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy.\n* Part B: may have had up to 2 prior regimens, no more than 1 of which may be endocrine therapy in the advanced/metastatic setting, and must have received a prior CDK4/6 inhibitor\n* Cohort E4: No prior everolimus.\n* Cohort E5: No prior alpelisib and must have a phosphatidylinositol 3-kinase catalytic \u03b1 (PIK3C\u03b1) mutation as determined by local testing.\n* Part C: ER+, human epidermal growth factor receptor 2 positive (HER2+) breast cancer with evidence of locally advanced unresectable or metastatic disease who have had at least 2 HER2-directed therapies in any setting.\n* Part D: ER+, EEC that has progressed after platinum containing chemotherapy and no prior fulvestrant or aromatase inhibitor therapy.\n* Part E: ER+ and HER2+ breast cancer with evidence of locally advanced, unresectable, or metastatic disease.\n* Part E: Participants must have received induction taxane chemotherapy combined with trastuzumab + pertuzumab as first-line treatment for advanced/metastatic disease and must not have progressed on this regimen.\n* Part E: Participants must not have received more than 1 HER2-directed regimen or any endocrine therapy for advanced disease or any prior CDK4/6 inhibitor therapy.\n\nParticipants with ER+/HER2- breast cancer enrolled in this study must have had evidence of clinical benefit while on endocrine therapy for at least 24 months in the adjuvant setting or at least 6 months in the advanced/metastatic setting or have untreated de novo metastatic breast cancer\n\nExclusion Criteria:\n\n* Participants must not have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled\n* Participants must not have another serious medical condition\n* Participants must not have cancer of the central nervous system that is unstable\n* Participants must not be pregnant or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}